Interferon (INF) signaling pathways (including INFα, INFβ, and INFγ) are required for the anti-tumor immune response and subsequent cancer cell death, and tumors with low INF activity are often resistant to immune checkpoint inhibitor therapies [160,161]. This evidence concerns the gene CBLIF and cancer.